Symbols / CERS Stock $2.71 -2.87% Cerus Corporation

Healthcare • Medical Devices • United States • NGM
CERS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Mr. William M. Greenman
Exch · Country NGM · United States
Market Cap 543.00M
Enterprise Value 560.67M
Income -9.55M
Sales 216.56M
FCF (ttm) 2.26M
Book/sh 0.34
Cash/sh 0.40
Employees 261
Insider 10d —
IPO Jan 31, 1997
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E inf
PEG —
P/S 2.51
P/B 8.04
P/C —
EV/EBITDA -346.95
EV/Sales 2.59
Quick Ratio 1.02
Current Ratio 1.63
Debt/Eq 142.57
LT Debt/Eq —
EPS (ttm) -0.05
EPS next Y 0.00
EPS Growth —
Revenue Growth 24.10%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-04-30
Earnings (prior) 2026-04-30
ROA -0.93%
ROE -15.37%
ROIC —
Gross Margin 52.99%
Oper. Margin -0.66%
Profit Margin -4.41%
Shs Outstand 200.37M
Shs Float 182.21M
Insider Own 3.41%
Instit Own 74.64%
Short Float 9.52%
Short Ratio 6.64
Short Interest 18.52M
52W High 3.15
vs 52W High -13.97%
52W Low 1.15
vs 52W Low 135.65%
Beta 1.77
Impl. Vol. 1.09%
Rel Volume 0.71
Avg Volume 2.28M
Volume 1.61M
Target (mean) $4.67
Tgt Median $5.00
Tgt Low $4.00
Tgt High $5.00
# Analysts 3
Recom Strong_buy
Prev Close $2.79
Price $2.71
Change -2.87%
About

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$4.67
Mean price target
2. Current target
$2.71
Latest analyst target
3. DCF / Fair value
$0.20
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.71
Low
$4.00
High
$5.00
Mean
$4.67

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-01 up BTIG Neutral → Buy $4
2025-02-21 reit Cantor Fitzgerald Overweight → Overweight $4
2024-10-17 main Stifel Buy → Buy $3
2024-05-03 main Cantor Fitzgerald Overweight → Overweight $4
2024-04-12 init Craig-Hallum — → Buy $5
2024-03-07 reit Stephens & Co. Equal-Weight → Equal-Weight $3
2024-03-06 reit Cantor Fitzgerald Overweight → Overweight $3
2023-01-20 down BTIG Buy → Neutral —
2020-05-27 main Stifel — → Buy $8
2020-04-16 main Stephens & Co. — → Overweight $7
2020-02-26 init BTIG — → Buy $7
2019-11-13 up BTIG Neutral → Buy —
2019-08-28 init Stifel — → Buy $7
2016-04-22 main BTIG — → Buy $10
2015-12-17 down Wedbush Outperform → Neutral $7
2015-04-24 init BTIG — → Buy $8
2015-02-27 main Cantor Fitzgerald — → Buy $7
2014-12-02 main MLV & Co. — → Buy $7
2014-05-06 main Cantor Fitzgerald — → Buy $7
2013-09-30 main Wedbush — → Outperform $8
News
RSS: Latest CERS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-06-02 WITNEY FRANKLIN R. PH.D. Director — 60,000 $0.00 $0
2026-06-02 NACHTSHEIM JAMI DOVER K Director — 60,000 $0.00 $0
2026-06-02 BJERKHOLT ERIC H Director — 60,000 $0.00 $0
2026-06-02 LUCENA ANN Director — 60,000 $0.00 $0
2026-06-02 SHAN HUA Director — 60,000 $0.00 $0
2026-06-02 GREGORY DEAN A. Director — 60,000 $0.00 $0
2026-05-29 JAYARAMAN VIVEK K. MBA Chief Operating Officer — 16,667 $3.00 $50,001
2026-05-01 JAYARAMAN VIVEK K. MBA Chief Operating Officer — 16,667 $3.00 $50,001
2026-04-01 GREEN KEVIN DENNIS Chief Financial Officer — 200,000 $0.00 $0
2026-04-01 JENSEN CHRYSTAL MENARD Officer — 200,000 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
206.13
+14.35%
180.27
+15.29%
156.37
-3.51%
162.05
Operating Revenue
206.13
+14.35%
180.27
+15.29%
156.37
-3.51%
162.05
Cost Of Revenue
93.84
+16.22%
80.75
+15.41%
69.97
-6.65%
74.95
Reconciled Cost Of Revenue
93.84
+16.22%
80.75
+15.41%
69.97
-6.65%
74.95
Gross Profit
112.29
+12.83%
99.52
+15.19%
86.40
-0.80%
87.09
Operating Expense
120.97
+6.35%
113.75
+0.91%
112.72
-6.97%
121.17
Research And Development
67.72
+14.96%
58.91
-12.91%
67.64
+5.51%
64.11
Selling General And Administration
80.91
+6.62%
75.89
+0.50%
75.52
-9.38%
83.33
Other Operating Expenses
-27.66
-31.42%
-21.05
+30.82%
-30.43
-15.85%
-26.27
Total Expenses
214.81
+10.45%
194.50
+6.46%
182.69
-6.85%
196.13
Operating Income
-8.68
+38.97%
-14.22
+45.96%
-26.32
+22.76%
-34.08
Total Operating Income As Reported
-8.68
+38.97%
-14.22
+52.67%
-30.05
+11.82%
-34.08
EBITDA
-5.51
+44.99%
-10.02
+61.94%
-26.34
+21.43%
-33.52
Normalized EBITDA
-4.24
+59.22%
-10.39
+52.67%
-21.96
+33.11%
-32.83
Reconciled Depreciation
1.43
-23.13%
1.85
-28.63%
2.60
-12.90%
2.98
EBIT
-6.94
+41.58%
-11.88
+58.95%
-28.94
+20.74%
-36.51
Total Unusual Items
-1.27
-444.59%
0.37
+108.46%
-4.38
-534.20%
-0.69
Total Unusual Items Excluding Goodwill
-1.27
-444.59%
0.37
+108.46%
-4.38
-534.20%
-0.69
Special Income Charges
0.00
0.00
+100.00%
-3.73
0.00
Restructuring And Mergern Acquisition
0.00
0.00
-100.00%
3.73
0.00
Net Income
-15.63
+25.29%
-20.92
+44.20%
-37.49
+12.37%
-42.78
Pretax Income
-15.28
+26.37%
-20.76
+44.39%
-37.32
+11.85%
-42.34
Net Non Operating Interest Income Expense
-8.34
+6.02%
-8.88
-5.85%
-8.39
-43.82%
-5.83
Interest Expense Non Operating
8.34
-6.02%
8.88
+5.85%
8.39
+43.82%
5.83
Net Interest Income
-8.34
+6.02%
-8.88
-5.85%
-8.39
-43.82%
-5.83
Interest Expense
8.34
-6.02%
8.88
+5.85%
8.39
+43.82%
5.83
Other Income Expense
1.74
-25.79%
2.35
+189.85%
-2.61
-7.67%
-2.42
Other Non Operating Income Expenses
3.02
+52.63%
1.98
+11.95%
1.76
+201.73%
-1.74
Gain On Sale Of Security
-1.27
-444.59%
0.37
+157.10%
-0.65
+6.09%
-0.69
Tax Provision
0.35
+72.68%
0.20
-36.92%
0.33
-33.40%
0.49
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-0.27
-444.59%
0.08
+108.46%
-0.92
-534.20%
-0.14
Net Income Including Noncontrolling Interests
-15.64
+25.40%
-20.96
+44.32%
-37.65
+12.09%
-42.83
Net Income From Continuing Operation Net Minority Interest
-15.63
+25.29%
-20.92
+44.20%
-37.49
+12.37%
-42.78
Net Income From Continuing And Discontinued Operation
-15.63
+25.29%
-20.92
+44.20%
-37.49
+12.37%
-42.78
Net Income Continuous Operations
-15.64
+25.40%
-20.96
+44.32%
-37.65
+12.09%
-42.83
Minority Interests
0.01
-76.74%
0.04
-72.78%
0.16
+243.48%
0.05
Normalized Income
-14.62
+31.07%
-21.21
+37.68%
-34.03
+19.42%
-42.23
Net Income Common Stockholders
-15.63
+25.29%
-20.92
+44.20%
-37.49
+12.37%
-42.78
Diluted EPS
-0.08
+27.27%
-0.11
+47.62%
-0.21
+12.50%
-0.24
Basic EPS
-0.08
+27.27%
-0.11
+47.62%
-0.21
+12.50%
-0.24
Basic Average Shares
190.59
+3.27%
184.56
+2.38%
180.27
+2.11%
176.54
Diluted Average Shares
190.59
+3.27%
184.56
+2.38%
180.27
+2.11%
176.54
Diluted NI Availto Com Stockholders
-15.63
+25.29%
-20.92
+44.20%
-37.49
+12.37%
-42.78
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
221.86
+10.42%
200.92
+1.60%
197.75
-9.33%
218.09
Current Assets
174.38
+14.71%
152.02
+5.25%
144.44
-15.11%
170.14
Cash Cash Equivalents And Short Term Investments
82.88
+3.02%
80.45
+22.17%
65.85
-35.54%
102.15
Cash And Cash Equivalents
19.96
-1.50%
20.27
+74.00%
11.65
-67.27%
35.59
Other Short Term Investments
62.92
+4.54%
60.19
+11.03%
54.20
-18.57%
66.57
Receivables
30.37
+2.00%
29.78
-16.12%
35.50
+3.12%
34.43
Accounts Receivable
30.37
+2.00%
29.78
-16.12%
35.50
+3.12%
34.43
Inventory
56.10
+47.05%
38.15
-4.31%
39.87
+37.46%
29.00
Prepaid Assets
—
—
—
—
Other Current Assets
5.03
+38.07%
3.64
+13.10%
3.22
-29.38%
4.56
Total Non Current Assets
47.48
-2.90%
48.90
-8.28%
53.31
+11.18%
47.95
Net PPE
19.33
+24.39%
15.54
-19.71%
19.35
-17.58%
23.48
Gross PPE
39.00
+14.79%
33.98
-5.16%
35.83
-4.97%
37.70
Accumulated Depreciation
-19.67
-6.69%
-18.44
-11.94%
-16.47
-15.87%
-14.22
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
11.84
-0.73%
11.93
+3.79%
11.49
+9.21%
10.52
Construction In Progress
2.90
0.00
0.00
-100.00%
0.42
Other Properties
12.07
+22.45%
9.86
-18.80%
12.14
-12.93%
13.95
Leases
12.19
-0.02%
12.19
+0.00%
12.19
-4.85%
12.81
Goodwill And Other Intangible Assets
1.32
+0.00%
1.32
+0.00%
1.32
+0.00%
1.32
Goodwill
1.32
+0.00%
1.32
+0.00%
1.32
+0.00%
1.32
Other Non Current Assets
26.83
-16.26%
32.04
-1.83%
32.64
+40.98%
23.15
Total Liabilities Net Minority Interest
156.89
+8.94%
144.02
-0.20%
144.30
-3.49%
149.53
Current Liabilities
100.80
+58.47%
63.61
-5.80%
67.52
-42.32%
117.06
Payables And Accrued Expenses
35.02
+22.02%
28.70
-8.15%
31.25
-23.09%
40.63
Payables
28.01
+29.10%
21.70
-9.01%
23.84
-27.76%
33.00
Accounts Payable
28.01
+29.10%
21.70
-9.01%
23.84
-27.76%
33.00
Current Accrued Expenses
7.01
+0.09%
7.00
-5.39%
7.40
-2.92%
7.63
Pensionand Other Post Retirement Benefit Plans Current
18.26
+52.95%
11.94
+0.99%
11.82
-32.74%
17.58
Current Debt And Capital Lease Obligation
46.25
+114.39%
21.57
-3.92%
22.45
-61.47%
58.26
Current Debt
43.34
+124.61%
19.30
-3.52%
20.00
-64.39%
56.16
Other Current Borrowings
43.34
+124.61%
19.30
-3.52%
20.00
-64.39%
56.16
Current Capital Lease Obligation
2.90
+27.69%
2.27
-7.22%
2.45
+16.48%
2.10
Current Deferred Liabilities
1.27
-8.87%
1.40
-30.17%
2.00
+239.90%
0.59
Current Deferred Revenue
1.27
-8.87%
1.40
-30.17%
2.00
+239.90%
0.59
Total Non Current Liabilities Net Minority Interest
56.09
-30.24%
80.41
+4.73%
76.78
+136.46%
32.47
Long Term Debt And Capital Lease Obligation
50.70
-33.75%
76.53
+4.05%
73.55
+153.85%
28.97
Long Term Debt
40.55
-37.49%
64.86
+8.47%
59.80
+338.26%
13.64
Long Term Capital Lease Obligation
10.15
-12.95%
11.66
-15.18%
13.75
-10.29%
15.33
Other Non Current Liabilities
5.39
+38.76%
3.89
+20.15%
3.24
-7.52%
3.50
Stockholders Equity
64.22
+14.39%
56.15
+6.64%
52.65
-22.13%
67.61
Common Stock Equity
64.22
+14.39%
56.15
+6.64%
52.65
-22.13%
67.61
Capital Stock
0.19
+3.23%
0.19
+2.76%
0.18
+2.26%
0.18
Common Stock
0.19
+3.23%
0.19
+2.76%
0.18
+2.26%
0.18
Preferred Stock
0.00
0.00
—
—
Share Issued
192.14
+3.43%
185.77
+2.49%
181.25
+2.06%
177.58
Ordinary Shares Number
192.14
+3.43%
185.77
+2.49%
181.25
+2.06%
177.58
Additional Paid In Capital
1,145.34
+2.09%
1,121.89
+2.14%
1,098.35
+1.95%
1,077.34
Retained Earnings
-1,081.15
-1.47%
-1,065.53
-2.00%
-1,044.61
-3.72%
-1,007.12
Gains Losses Not Affecting Retained Earnings
-0.16
+61.00%
-0.40
+68.60%
-1.27
+54.29%
-2.79
Minority Interest
0.74
-1.33%
0.75
-5.42%
0.79
-16.60%
0.95
Other Equity Adjustments
-0.16
+61.00%
-0.40
+68.60%
-1.27
+54.29%
-2.79
Total Equity Gross Minority Interest
64.97
+14.18%
56.90
+6.46%
53.44
-22.05%
68.56
Total Capitalization
104.77
-13.42%
121.01
+7.61%
112.45
+38.39%
81.25
Working Capital
73.58
-16.77%
88.41
+14.94%
76.92
+44.90%
53.09
Invested Capital
148.11
+5.57%
140.30
+5.93%
132.45
-3.61%
137.41
Total Debt
96.95
-1.17%
98.10
+2.19%
96.00
+10.04%
87.24
Net Debt
63.93
+0.05%
63.89
-6.25%
68.15
+99.16%
34.22
Capital Lease Obligations
13.06
-6.31%
13.94
-13.98%
16.20
-7.06%
17.43
Net Tangible Assets
62.91
+14.73%
54.83
+6.81%
51.33
-22.57%
66.29
Tangible Book Value
62.91
+14.73%
54.83
+6.81%
51.33
-22.57%
66.29
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
4.84
-57.42%
11.36
+126.31%
-43.17
-68.53%
-25.61
Cash Flow From Continuing Operating Activities
4.84
-57.42%
11.36
+126.31%
-43.17
-68.53%
-25.61
Net Income From Continuing Operations
-15.64
+25.40%
-20.96
+44.32%
-37.65
+12.09%
-42.83
Depreciation Amortization Depletion
1.43
-23.13%
1.85
-28.63%
2.60
-12.90%
2.98
Depreciation And Amortization
1.43
-23.13%
1.85
-28.63%
2.60
-12.90%
2.98
Other Non Cash Items
2.93
+1.74%
2.88
+7.38%
2.68
+22.80%
2.18
Stock Based Compensation
22.87
+0.00%
22.87
+12.81%
20.27
-17.11%
24.46
Asset Impairment Charge
0.00
0.00
-100.00%
1.70
0.00
Operating Gains Losses
0.28
+175.13%
-0.38
+33.22%
-0.57
-113.47%
4.20
Gain Loss On Investment Securities
-0.01
-185.71%
0.01
-87.04%
0.05
-97.64%
2.29
Unrealized Gain Loss On Investment Securities
-0.20
-51.11%
-0.14
+20.59%
-0.17
+69.86%
-0.56
Net Foreign Currency Exchange Gain Loss
0.29
+174.74%
-0.39
+43.36%
-0.69
-135.85%
1.91
Gain Loss On Sale Of PPE
0.00
-100.00%
0.00
-95.38%
0.07
0.00
Change In Working Capital
-6.83
-230.55%
5.23
+116.33%
-32.03
-99.57%
-16.05
Change In Receivables
-0.40
-107.19%
5.50
+599.46%
-1.10
+88.02%
-9.20
Changes In Account Receivables
-0.40
-107.19%
5.50
+599.46%
-1.10
+88.02%
-9.20
Change In Inventory
-14.68
-308.85%
7.03
+147.03%
-14.95
-745.42%
-1.77
Change In Prepaid Assets
-1.63
+46.21%
-3.02
-204.33%
-0.99
-185.10%
1.17
Change In Payables And Accrued Expense
10.00
+372.11%
-3.67
+77.60%
-16.41
-165.97%
-6.17
Change In Accrued Expense
4.28
+294.49%
-2.20
+75.77%
-9.07
-618.13%
-1.26
Change In Payable
5.72
+487.61%
-1.48
+79.86%
-7.33
-49.54%
-4.91
Change In Account Payable
5.72
+487.61%
-1.48
+79.86%
-7.33
-49.54%
-4.91
Change In Other Working Capital
-0.12
+79.44%
-0.60
-142.68%
1.41
+1782.14%
-0.08
Change In Other Current Assets
—
—
—
—
Investing Cash Flow
-6.17
+24.17%
-8.13
-194.27%
8.62
+1.89%
8.46
Cash Flow From Continuing Investing Activities
-6.17
+24.17%
-8.13
-194.27%
8.62
+1.89%
8.46
Capital Expenditure
-3.73
-31.44%
-2.84
+38.29%
-4.60
-129.85%
-2.00
Capital Expenditure Reported
-3.73
-31.44%
-2.84
+38.29%
-4.60
-129.85%
-2.00
Net Investment Purchase And Sale
-2.44
+53.98%
-5.29
-140.03%
13.22
+26.35%
10.46
Purchase Of Investment
-42.78
+0.46%
-42.98
-1628.68%
-2.49
+91.61%
-29.64
Sale Of Investment
40.34
+7.06%
37.68
+139.91%
15.71
-60.83%
40.10
Financing Cash Flow
0.23
-95.35%
4.96
-53.49%
10.67
+154.60%
4.19
Cash Flow From Continuing Financing Activities
0.23
-95.35%
4.96
-53.49%
10.67
+154.60%
4.19
Net Issuance Payments Of Debt
-0.33
-107.66%
4.30
-56.70%
9.92
+4580.66%
0.21
Issuance Of Debt
0.00
-100.00%
5.00
-49.61%
9.92
+4580.66%
0.21
Repayment Of Debt
-0.33
+53.20%
-0.70
—
—
Long Term Debt Issuance
0.00
-100.00%
5.00
-49.61%
9.92
+4580.66%
0.21
Long Term Debt Payments
-0.33
+53.20%
-0.70
—
—
Net Long Term Debt Issuance
-0.33
-107.66%
4.30
-56.70%
9.92
+4580.66%
0.21
Short Term Debt Issuance
—
—
5.09
+2301.42%
0.21
Short Term Debt Payments
—
-0.70
—
—
Net Short Term Debt Issuance
—
-0.70
-113.81%
5.09
+2301.42%
0.21
Net Common Stock Issuance
—
—
-0.17
-68.27%
-0.10
Common Stock Payments
—
—
-0.17
-68.27%
-0.10
Repurchase Of Capital Stock
—
—
-0.17
-68.27%
-0.10
Proceeds From Stock Option Exercised
0.59
-26.00%
0.80
-13.08%
0.93
-77.35%
4.08
Net Other Financing Charges
-0.04
+74.45%
-0.14
+21.71%
-0.17
-68.27%
-0.10
Changes In Cash
-1.10
-113.39%
8.19
+134.32%
-23.87
-84.20%
-12.96
Effect Of Exchange Rate Changes
0.34
+275.92%
-0.19
-49.22%
-0.13
+82.39%
-0.73
Beginning Cash Position
21.36
+59.90%
13.36
-64.24%
37.36
-26.81%
51.04
End Cash Position
20.60
-3.56%
21.36
+59.90%
13.36
-64.24%
37.36
Free Cash Flow
1.11
-87.00%
8.52
+117.84%
-47.77
-72.97%
-27.61
Interest Paid Supplemental Data
8.52
-8.33%
9.29
+0.92%
9.21
+80.59%
5.10
Income Tax Paid Supplemental Data
0.30
-15.45%
0.36
+10.56%
0.32
+19.26%
0.27
Common Stock Issuance
—
—
—
—
Issuance Of Capital Stock
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category